Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
Post-TAVR stroke is rare, but it can be fatal. A new study in Catheterization and Cardiovascular Interventions examined the issue in great detail, focusing on more than 2,700 patients treated over a two-year stretch.
Gregg Stone, MD, discussing the value of IVUS and OCT over angiography to guide PCI procedures and actually improve outcomes based on a 12,000 patient meta analysis presented at ESC 2023.
NCDR report finds hospitals are seeing improvements but are still struggling to reach pre-COVID treatment thresholds years after pandemic precautions upended longstanding processes.
“Given the dramatic difference in death risk for older adults receiving complex PCI, we suggest that such interventions in this exceptionally vulnerable population should be approached with additional caution," researchers wrote.
The FDA is expected to base its decision in part on the STELLAR clinical trial, which included 163 adult patients treated with subcutaneous sotatercept and 160 patients treated with a placebo.
The popular SGLT2 inhibitor, sold by Boehringer Ingelheim and Eli Lilly and Company under the name Jardiance, has already been approved by the FDA to treat type 2 diabetes and heart failure.
Some heart teams may only target the culprit lesions when treating older patients, but new research confirms this increases the risk of several unfavorable outcomes.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
